December 2, 2025
1 min read

Pharmas have promised $370B in US investments amid 2025’s onshoring boom: DPR

Even as moving tariff targets and a capricious market have injected uncertainty into the operations of many biopharma players this year, it’s hard to deny the effect that President Donald Trump’s trade duties have had on industry investment in the U.S.

Leave a Reply

Your email address will not be published.

Previous Story

STAT+: Marion Nestle still believes that ‘calories count’

Next Story

Lawmakers dig in on biopharma manufacturing with bill proposing US center of excellence

Previous Story

STAT+: Marion Nestle still believes that ‘calories count’

Next Story

Lawmakers dig in on biopharma manufacturing with bill proposing US center of excellence

Latest from Blog

ROFI Drives New Approach to Crop Nutrition

With input costs continuing to pressure farm budgets, some growers are making difficult decisions to reduce fertilizer application rates. While that strategy may ease upfront expenses, it is also accelerating a broader
Go toTop